Australia Markets open in 43 mins

Living Cell Technologies Limited (LVCLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00470.0000 (0.00%)
At close: 01:30PM EDT

Living Cell Technologies Limited

Tower 2
Level 16 Darling Park 201 Sussex Street
Sydney, NSW 2000
61 3 8689 9997

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Daya UkaChief Financial Officer121.86kN/AN/A
Dr. Belinda Di BartoloChief Operations Officer101.29kN/AN/A
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSPCompany Sec.N/AN/A1964
Mr. Madhukar BhallaCompany Sec.N/AN/A1959
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.

Corporate governance

Living Cell Technologies Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.